VIR - Vir Biotechnology

-

$undefined

N/A

(N/A)

Vir Biotechnology NasdaqGS:VIR Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Location: 1800 Owens Street, San Francisco, CA, 94158, United States | Website: https://www.vir.bio | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

11.89M

Cash

801.7M

Avg Qtr Burn

-103.8M

Short % of Float

11.64%

Insider Ownership

22.66%

Institutional Own.

79.13%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tobevibart + Elebsiran Details
Infectious disease, Hepatitis Delta Virus

Phase 3

Data readout

Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Phase 3

Update

Phase 2

Data readout

VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details
Infectious disease, Hepatitis B

Phase 2

Data readout

VIR-2482 (Universal prophylaxis) Details
Influenza, Infectious disease

Phase 2

Update

VIR-5818 + Pembrolizumab Details
Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer

Phase 1

Data readout

VIR-5500 Details
Metastatic castration resistant prostate cancer (mCRPC)

Phase 1

Data readout

VIR-1388 (HVTN 142) Details
Infectious disease, Human immunodeficiency virus, Vaccine

Phase 1

Data readout

VIR-5525 Details
Cancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer

Phase 1

Initiation

VIR-1111 Details
Infectious disease, Human immunodeficiency virus, Vaccine

Failed

Discontinued

Sotrovimab VIR-7831 (GSK4182136) Details
COVID-19, Infectious disease

Failed

Discontinued